Mistletoe (VAE) †Rx
Rx extract: Lectin apoptosis, NK/cytokine ↑, QoL ↑; moderate adjunct signals in breast/lung/pancreatic/colorectal.
Forms: Subcutaneous ampoules (standardized lectin/viscotoxin) · IV infusion (for advanced settings)
Key Takeaway
Injectable Viscum album extracts can trigger lectin-mediated tumor apoptosis and modulate immunity (NK/CTL, IL-12/TNF-α). Across mixed-quality human studies, VAE frequently improves quality of life and treatment tolerance; disease-control benefits appear context- and product-dependent.
Evidence at a glance
50+ RCTs/observational studies; meta-QoL benefits (SMD 0.3-0.5); survival OS HR 0.7-0.9 in subsets; US IV phase I ongoing (NCT05165405); product heterogeneity limits pooling.
How it may work
VAE contains lectins (RIP-II) and viscotoxins. Lectins bind cell-surface carbohydrates, internalize, and depurinate rRNA (N-glycosidase), inhibiting protein synthesis and inducing apoptosis. Pattern-recognition signaling (e.g., TLR/Dectin-like) raises IL-12/TNF-α, enhances NK/CTL cytotoxicity, and may reduce angiogenic factors. Clinical literature reports QoL gains, symptom relief, and some survival signals when used adjunctively with chemo/radiation, with heterogeneity by extract type, dose, and tumor site.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
Often studied / combined with
Combinations reported in the literature, not a protocol or a recommendation.
- Gemcitabine: Better tolerance and PFS in pancreatic adjunct trials.
- Cisplatin: Amplified NK/Th1 response in lung cancer models.
- Curcumin: Cooperative cytokine/apoptosis in colorectal.
- Resveratrol: Enhanced lectin-mediated kill in breast preclinical.
Overlapping mechanisms
- Immune (NK): Overlaps with other β-glucan/lectin immunomodulators.
- Cytokines: Th1 skew may saturate with multi-immune agents; monitor inflammation.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
- immunotherapiesMonitorModerateTheoreticalCytokine overlap; potential for additive immune activation.
- chemotherapySynergizeLowTheoreticalEnhances tolerance without efficacy loss.
- GemcitabineSynergizeLowTheoreticalImproved QoL and possible PFS in pancreatic.
Timing
- AM: SubQ in morning to observe reactions during day.
- 2-3x/week: Spaced injections for cumulative effects.
References
- PMC9398055: Mistletoe extract in cancer therapy review
- DOI 10.1007/s00432-022-04511-2: QoL and survival in breast cancer
- DOI 10.3390/curroncol30090495: Immunomodulatory effects
- Hopkins Mistletoe Study 2023: Phase I IV VAE trial
- DOI 10.3390/cancers15123185: Synergy with gemcitabine in pancreatic models
- PMC10221542: Combination with curcumin in colorectal cancer
Research
No published studies for Mistletoe (VAE) †Rx yet
New studies appear here once they’ve been reviewed. Browse all studies.
Dose: as studied, not a recommendation
Ranges seen in adjunct / practice use: 0.01–20 mg SC 2-3x/week (SC) Slow titration (e.g., 0.01→0.2→2→10 mg); individualize by reaction, Protocol-dependent (e.g., Iscador M 0.01-20 mg SC 2x/wk); monitor local/systemic response; IV trials 10-200 mg/week..
Trials studying Mistletoe (VAE) †Rx
No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →